Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - The report reviews Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview 6 Therapeutics Development 7 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Stage of Development 7 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Therapy Area 8 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Indication 9 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Companies 12 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Companies Involved in Therapeutics Development 20 AbbVie Inc 20 Handok Inc 21 XBiotech Inc 22 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Drug Profiles 23 ABT-981 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CV-18C3 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HL-2351 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 RA-18C3 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 T-218C3 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Xilonix - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Dormant Projects 35 Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Featured News & Press Releases 36 Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer 36 Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection 36 Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU 37 Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer 37 Jul 02, 2016: XBiotech Presents Pivotal Phase III Data Showing Xilonix Demonstrated Significant Clinical Response in Advanced Colorectal Cancer Patients Refractory to Further Treatment 39 Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio 40 May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer 41 Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology's World Congress on Gastrointestinal Cancer 41 Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech's True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer 42 Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer 43 Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency 43 Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech's Marketing Authorization Application 44 Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament 45 Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium 45 Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by AbbVie Inc, H2 2016 20 Pipeline by Handok Inc, H2 2016 21 Pipeline by XBiotech Inc, H2 2016 22 Dormant Projects, H2 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.